Role of glucagon-like peptide 1 receptor agonists in management of obesity

American Journal of Health-System Pharmacy

Volumn 73, Issue 19, 2016, Pages 1493-1507

  Isaacs, Diana ^a,b   Prasad Reddy, Lalita ^a,c   Srivastava, Sneha Baxi ^a,d  

^a CHICAGO STATE UNIVERSITY   (United States)

^b HINES VA HOSPITAL   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Access Community Health Network (ACCESS)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DRUG EFFECT; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; NAUSEA; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING; WEIGHT REDUCTION; AGONISTS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LIFESTYLE; TREATMENT OUTCOME; UNITED STATES;

ANTI-OBESITY AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; OBESITY; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; TREATMENT OUTCOME; UNITED STATES; WEIGHT LOSS;

EID: 84989951285     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150990     Document Type: Review

References (52)

1. Goo Kang J, Young-Park C. Obesity drugs: review about their effects and safety. Diabetes Metab J. 2012; 36:13-25.
2. Neff L, Kushner R. Emerging role of GLP-1 RAs in the treatment of obesity. Diabetes Metab Syndr Obes. 2010; 3:263-73.
3. Monami M, Dicembrini I, Nardini C et al. Effects of glucagonlike peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014; 16:38-47.
4. Saxenda (liraglutide) package insert. Plainsboro, NJ: Novo Nordisk; 2015.
5. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-14.
6. Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100:342-62.
7. American College of Cardiology/American Heart Association/The Obesity Society. 2013 AHA/ACC/TOC guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014; 63:2985-3023.
8. Department of Health and Human Services. Managing overweight and obesity in adults: a systematic evidence review from the obesity expert panel, 2013. www.nhlbi. nih.gov/sites/www.nhlbi.nih.gov/fles/obesity-evidence-review.pdf (accessed 2015 Sep 15).
9. Kumar R, Aronne L. Effcacy comparison of medications approved for chronic weight management. Obesity. 2015; 23:S4-S7.
10. Centers for Disease Control and Prevention. Body mass index: considerations for practitioners. www.cdc.gov/obesity/downloads/BMIforPractitioners.pdf (accessed 2016 Apr 20).
11. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014; 311:74-86.
12. Wadden TA, Volger S, Tsai AG et al. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. Int J Obes. 2013; 37(suppl 1):S3-11.
13. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014; 95:53-66.
14. Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother. 2013; 47:1007-16.
15. Drucker D. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368:1696-705.
16. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: effcacy and safety in diabetes and beyond. Drugs Context. 2015; 4:212283.
17. Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity. 2015; 23:1119-29.
18. Novo Nordisk. Novo Nordisk successfully completes second phase 3a trial with semaglutide in people with type 2 diabetes (September 25, 2015). www.novonordisk.com/bin/getPDF.1954507.pdf (accessed 2015 Sep 29).
19. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373:11-22.
20. Astrup A, Rossner S, van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind placebo-controlled study. Lancet. 2009; 374:1606-16.
21. Davies MJ, Bergenstal R, Bode B et al. Effcacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA. 2015; 314:687-99.
22. Niswender K, Pi-Sunyer X, Buse J et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013; 15:42-54.
23. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013; 37:1443-51.
24. Astrup A, Carraro R, Finer N et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012; 36:843-54.
25. Danne T, Biester T, Kapitzke K et al. A phase 1, randomized, double-blind, placebo-controlled trial to assess safety, tolerability and pharmacokinetics of liraglutide in obese adolescent subjects aged 12 to 17 years. https://endo.confex.com/endo/2016endo/webprogram/Paper24745.html (accessed 2016 Apr 27).
26. Sever MJ, Kocjan T, Pfeifer M et al. Short-term combined treatment with liraglutide and metformin leads to signifcant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014; 170:451-9.
27. Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol. 2014; 5:140.
28. Blackman A, Foster GD, Zammit G et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). Epub ahead of print. 2016 Mar 23.
29. Kim SH, Abbasi F, Lamendola C et al. Benefts of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013; 36:3276-82.
30. Moretto TI, Milton DR, Ridge TD et al. Effcacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group study. Clin Ther. 2008; 30:1448-60.
31. DeFronzo RA, Raner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28:1092-100.
32. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27:2628-35.
33. Heine RJ, van Gaal L F, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143:559-69.
34. Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33:1255-61.
35. Wysahm CH, MacConell LA, Maggs DG et al. Five-year effcacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Mayo Clin Proc. 2015; 90:356-65.
36. Dushay J, Gao C, Gopalakrishnan GS et al. Short-term exenatide treatment leads to signifcant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012; 35:4-11.
37. Rosenstock J, Klaff LJ, Schwart S et al. Effects of exenatide and lifestyle modifcation on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010; 33:1173-5.
38. Kelly AS, Rudser KD, Nathan BM et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013; 167:355-60.
39. Ahren B, Johnson SL, Stewart M et al. HARMONY-3: 104-week randomized, double-blind, placebo-and active-controlled trial assessing the effcacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014; 37:2141-8.
40. Pratley RE, Nauck MA, Barnett AH et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomized, open-label, multicenter, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014; 2:289-97.
41. Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014; 34:1174-86.
42. Wysham C, Blevins T, Arakaki R et al. Effcacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014; 37:2159-67.
43. Nauck M, Weinstock RS, Umpierrez GE et al. Effcacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014; 37:2149-58.
44. Dungan KM, Povedano ST, Forst T et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384:1349-57.
45. Pinget M, Goldenberg R, Niemoeller E. Effcacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insuffciently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013; 15:1000-7.
46. Rosenstock J, Raccah D, Koranyi L et al. Effcacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active controlled study (GetGoal-X). Diabetes Care. 2013; 36:2945-51.
47. Nauck M, Rizzo M, Pirags V et al. Once-daily liraglutide vs. lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomised controlled clinical trial. Abstract presented at 51st Annual Meeting of European Association of Diabetes (EASD). Stockholm, Sweden; 2015 Sep 14-18.
48. Vilsbøl T, Christensen M, Junker A et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: a systematic review and meta-analysis of randomized controlled trials. BMJ. 2012; 344:d7771.
49. Sun F, Chai S, Li L et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015; 2015:157201.
50. Katout M, Zhu H, Rutsky J et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014; 27:130-9.
51. Nauck MA, Petrie JR, Sesti G et al. A phase 2, randomized, dose-fnding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2014; 37:2149-58.
52. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. A review of their effcacy and tolerability. Diabetes Care. 2011; 34(suppl 2):S279-84.